DNAP news: DNAPrint Files for Second Software Patent
SARASOTA, Fla.--(BUSINESS WIRE)--March 20, 2001--DNAPrint genomics, Inc. (OTCBB:DNAP - news) announced today that the company has filed a
second provisional patent application with the United States Patent & Trademark Office (USPTO).
The application, entitled ``METHODS AND APPARATUS FOR QUALITY CONTROL PROCESSING OF GENE SEQUENCE DATA,'' teaches an in-silico
method for isolating, analyzing and storing single nucleotide polymorphisms (SNPs) in terms of genetic haplotypes. Earlier this year, the company announced the filing
of its first provisional patent application that covers related but distinct methodologies.
The new method constitutes part of the companies SNiPdoc(SM) informatics platform. The company uses this platform to mine complex genetic relationships
between genes, environmental factors and drug reactivity/disease traits for the development of genomics-based diagnostic products.
``Proprietary infrastructure and analytical tools for the high-throughput analysis of human genetic variation are the cornerstone of our competitive advantage in the
pharmaco/disease genomics field,'' said Dr. Tony Frudakis, CEO of DNAprint genomics, Inc. ``As a team, we are proud to announce to our investors that we have
filed for intellectual property protection of another such important and valuable tool.''
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and
molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company,
please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as
amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to,
uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on
collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc.
expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any
change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
DNAPrint genomics Inc., Sarasota
For scientific inquiries:
Dr. Tony Frudakis, 941/351-4543
or
All other inquiries:
Richard Craig Hall, 941/341-0136 |
